NCT04127123

Withdrawn

Cloud-Based Mapping for Personalized Ablation

Stanford University Source

Compare

Other study identifiers

Sponsor study identifier

49800

Secondary identifiers

49800

OTHER · Stanford IRB

Study Type

observational

Actual enrollment (reported)

0

Locations

1 country

Sites

1

Timeline

Study Start

July 3, 2019

Actual (reported)

Primary Completion

December 30, 2020

Actual (reported)

Study Completion

January 11, 2021

Actual (reported)

Brief Summary

Atrial fibrillation is a serious public health issue that affects over 5 million Americans in whom it may cause skipped beats, dizziness, stroke and even death. This study seeks to improve our understanding of the causes of atrial fibrillation and to design new and more effective therapy for this heart rhythm disorder.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: withdrawn
Actual enrollment (reported): 0 participants
Study completion date: January 11, 2021
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
April 1, 2019
Actual (reported)
Study Start
July 3, 2019
Actual (reported)
First Posted
October 15, 2019
Actual (reported)
Primary Completion
December 30, 2020
Actual (reported)
Study Completion
January 11, 2021
Actual (reported)

Last Updated: May 7, 2021
Status Verified: May 2021
Last Update Submitted: May 4, 2021

Conditions

Arrhythmias, Cardiac Atrial Fibrillation

Keywords

arrhythmiacardiac electrophysiologyablation

Outcome Measures

Primary Outcomes (2)

Mapping Accuracy
Location of driver regions for AF
During Procedure (Electrophysiology Study and Ablation)
Termination of atrial fibrillation
Does ablation at any driver region lead to AF termination
During Procedure (Electrophysiology Study and Ablation)

Eligibility Criteria

Age21 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Subjects will be men and women of any ethnicity aged 21-80 years undergoing ablation at Stanford of AF. Patients will have failed or be intolerant of ≥ 1 anti-arrhythmic drug or not willing to accept antiarrhythmic drug therapy. 50 patients will be enrolled at Stanford University over 1-2 years.

You may qualify if:

men and women of any ethnicity

Sponsors & Collaborators

Stanford University
Otherlead

Study Sites (1)

Stanford University

Stanford, California, 94305, United States

MeSH Terms

Conditions

Atrial FibrillationArrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Sanjiv Narayan, MD, PhD
Stanford University
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor of Medicine

Study Record Dates

First Submitted

April 1, 2019

First Posted

October 15, 2019

Study Start

July 3, 2019

Actual (reported)

NCT04549714

Quantitative Ablation of Pulmonary Vein Vestibule in Paroxysmal Atrial Fibrillation.

Not ApplicableUnknown

NCT02758002

Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms

Not ApplicableWithdrawn

NCT04685317

Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation

Not ApplicableRecruiting

NCT04766814

Epigenetic Analysis of Regulation of the Inflammasome-activating NLRP3 Gene in Monocytes From Atrial Fibrillation Patients and Controls

Completed

NCT04476524

Clinical and Economic Impact of an Organized Treatment Pathway on AFib Patient Management From the ER

Unknown

NCT00578617

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

Not ApplicableCompleted

aged 21-80 years

undergoing ablation of atrial fibrillation at Stanford University

failed or be intolerant of ≥ 1 anti-arrhythmic drug or not willing to accept antiarrhythmic drug therapy.

You may not qualify if:

active coronary ischemia or decompensated heart failure
atrial or ventricular clot on trans-esophageal echocardiography
pregnancy (to minimize fluoroscopic exposure)
inability or unwillingness to provide informed consent
rheumatic valve disease (because it results in a unique AF phenotype)
thrombotic disease or venous filters
significantly reduced kidney function

Contact the study team to confirm eligibility.

Primary Completion

December 30, 2020

Actual (reported)

Study Completion

January 11, 2021

Actual (reported)

Last Updated

May 7, 2021

Record last verified: 2021-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04127123
Data provider: ClinicalTrials.gov
Source updated: 2021-05-07
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:59 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations